Valuation: Alumis Inc.

Market Cap 867M 772M 715M 648M 1.22B 82.15B 1.24B 8.58B 3.37B 42.99B 3.25B 3.19B 137B P/E 2026 *
-2.05x
P/E 2027 * -2.38x
Enterprise Value 151M 135M 125M 113M 212M 14.33B 216M 1.5B 588M 7.5B 567M 555M 23.92B EV / Sales 2026 *
24.2x
EV / Sales 2027 * 14.5x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+5.68%
1 week+2.13%
Current month-9.34%
1 month-13.77%
3 months-76.05%
6 months-72.89%
Current year-31.35%
1 week 6.01
Extreme 6.01
6.72
1 month 6.01
Extreme 6.01
8.14
Current year 6.01
Extreme 6.01
31.35
1 year 4.37
Extreme 4.37
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Director/Board Member 55 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26
Samsara BioCapital LLC
SellCompany -642,712 0.5207%
9/4/26 Other

Director

0 0%
8/3/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+5.68%+2.13%+40.76% - 821M
+0.79%-6.16%+49.32%+74.50% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.85%+17.04%+59.17% 34B
+0.20%+0.44%+38.70%+8.26% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +2.96%+1.71%+50.76%+123.18% 37.66B
Weighted average by Cap. +2.79%+2.01%+50.17%+125.23%

Financials

2026 *2027 *
Net sales 6.26M 5.57M 5.17M 4.68M 8.8M 593M 8.94M 61.98M 24.35M 310M 23.49M 23M 990M 24.33M 21.66M 20.07M 18.19M 34.19M 2.31B 34.76M 241M 94.63M 1.21B 91.28M 89.39M 3.85B
Net income -427M -380M -352M -319M -600M -40.48B -610M -4.23B -1.66B -21.18B -1.6B -1.57B -67.58B -409M -364M -337M -305M -574M -38.71B -584M -4.05B -1.59B -20.26B -1.53B -1.5B -64.63B
Net Debt -716M -637M -591M -535M -1.01B -67.83B -1.02B -7.09B -2.78B -35.5B -2.69B -2.63B -113B -514M -457M -424M -384M -722M -48.68B -734M -5.09B -2B -25.48B -1.93B -1.89B -81.27B
Projected Income Statement - Annual - Alumis Inc.
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
26-10-20 US$6.700 +5.68% 1,534,748
26-10-19 US$6.340 +3.59% 1,483,718
26-10-16 US$6.120 -3.01% 2,496,575
26-10-15 US$6.310 +4.13% 2,786,515
26-10-14 US$6.060 -7.62% 2,298,082
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Alumis Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.700USD
Average target price
31.12USD
Spread / Average Target
+364.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alumis Inc.
  1. Stock Market
  2. Stocks
  3. ALMS Stock